Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage |
| Type de publication | Journal Article |
| Year of Publication | 2018 |
| Auteurs | Seiffge DJ, Kagi G, Michel P, Fischer U, Bejot Y, Wegener S, Zedde M, Turc G, Cordonnier C, Sandor PS, Rodier G, Zini A, Cappellari M, Schadelin S, Polymeris AA, Werring D, Thilemann S, Maestrini I, Berge E, Traenka C, Vehoff J, De Marchis GMarco, Kapauer M, Peters N, Sirimarco G, Bonati LH, Arnold M, Lyrer PA, De Maistre E, Luft A, Tsakiris DA, Engelter ST, Stroke NOral Antic |
| Journal | ANNALS OF NEUROLOGY |
| Volume | 83 |
| Pagination | 451-459 |
| Date Published | MAR |
| Type of Article | Article |
| ISSN | 0364-5134 |
| Résumé | {ObjectiveInformation about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. MethodsIn a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS patients had RivLev100ng/ml, indicating possible eligibility for thrombolysis, and how many ICH patients had RivLev75ng/ml, making them possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation, regression models) and studied the sensitivity and specificity of international normalized ratio (INR) thresholds to substitute RivLev using cross tables and receiver operating characteristic curves. ResultsAmong 241 patients (median age=80 years, interquartile range [IQR]=73-84; median time from onset to admission=2 hours |
| DOI | 10.1002/ana.25165 |